Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sharp Therapeutics Corp. ( (TSE:SHRX) ) has issued an announcement.
Sharp Therapeutics Corp. has engaged Rho, Inc., a global contract research organization, to assist in the preparation and submission of its Investigational New Drug Application to the FDA for its clinical candidate compound ‘901, aimed at treating Gaucher disease. This collaboration marks a significant milestone for Sharp as it transitions from a preclinical-stage to a clinical-stage company, with plans to commence IND-enabling studies by the end of 2025. The ‘901 compound shows promise as an orally available, CNS-penetrant therapy for Gaucher disease, with potential applications for GBA-associated Parkinson’s disease.
More about Sharp Therapeutics Corp.
Sharp Therapeutics is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics for genetic diseases. The company utilizes a discovery platform that combines high throughput screening technologies with computationally optimized compound libraries to create small molecule compounds aimed at restoring activity in mutated proteins, potentially treating genetic disorders with conventional pill-based medicines.
Average Trading Volume: 666
Technical Sentiment Signal: Sell
Find detailed analytics on SHRX stock on TipRanks’ Stock Analysis page.